Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

James, ND and Sydes, MR and Clarke, NW and Mason, MD and Dearnaley, DP and Spears, MR and Ritchie, AWS and Parker, CC and Russell, JM and Attard, G and De Bono, J and Cross, W and Jones, RJ and Thalmann, G and Amos, C and Matheson, D and Millman, R and Alzouebi, M and Beesley, S and Birtle, AJ and Brock, S and Cathomas, R and Chakraborti, P and Chowdhury, S and Cook, A and Elliott, T and Gale, J and Gibbs, S and Graham, JD and Hetherington, J and Hughes, R and Laing, R and McKinna, F and McLaren, DB and O'Sullivan, JM and Parikh, O and Peedell, C and Protheroe, A and Robinson, AJ and Srihari, N and Srinivasan, R and Staffurth, J and Sundar, S and Tolan, S and Tsang, D and Wagstaff, J and Parmar, MKB (2015) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet, 387 (10024). 1163 - 1177. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(15)01037-5

More Information

Divisions: Carnegie > Education & Childhood
Identification Number: https://doi.org/10.1016/S0140-6736(15)01037-5
Status: Published
Refereed: Yes
Date Deposited: 05 Apr 2016 12:53
Last Modified: 29 Jul 2016 13:10
Item Type: Article

Download

[img]
Preview

Export Citation

Share

Statistics

Additional statistics for this record